艰难梭菌感染的医学治疗进展。

IF 4.1 3区医学 Q1 IMMUNOLOGY

Infectious disease clinics of North America Pub Date : 2025-08-20 DOI:10.1016/j.idc.2025.07.005

Nirja Mehta, Colleen Kraft, Stuart Johnson

{"title":"艰难梭菌感染的医学治疗进展。","authors":"Nirja Mehta, Colleen Kraft, Stuart Johnson","doi":"10.1016/j.idc.2025.07.005","DOIUrl":null,"url":null,"abstract":"Clostridioides difficile medical management has changed significantly over the past decade with emphasis on preventing recurrent infection. This review compares current guidelines on the treatment of initial, recurrent, fulminant, and pediatric C difficile infection (CDI) and evaluates the mechanisms and clinical use of available antibiotics for CDI. C difficile has complex resistance mechanisms to vancomycin, fidaxomicin, and metronidazole which may play a role in treatment outcomes. Antibiotics such as tigecycline and rifaximin as well as monoclonal antibodies against toxin B may play a role in adjunctive therapy. Additional therapies under development include new narrow therapeutic antibiotics.","PeriodicalId":13562,"journal":{"name":"Infectious disease clinics of North America","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in the Medical Treatment of Clostridioides difficile Infection.\",\"authors\":\"Nirja Mehta, Colleen Kraft, Stuart Johnson\",\"doi\":\"10.1016/j.idc.2025.07.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Clostridioides difficile medical management has changed significantly over the past decade with emphasis on preventing recurrent infection. This review compares current guidelines on the treatment of initial, recurrent, fulminant, and pediatric C difficile infection (CDI) and evaluates the mechanisms and clinical use of available antibiotics for CDI. C difficile has complex resistance mechanisms to vancomycin, fidaxomicin, and metronidazole which may play a role in treatment outcomes. Antibiotics such as tigecycline and rifaximin as well as monoclonal antibodies against toxin B may play a role in adjunctive therapy. Additional therapies under development include new narrow therapeutic antibiotics.\",\"PeriodicalId\":13562,\"journal\":{\"name\":\"Infectious disease clinics of North America\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious disease clinics of North America\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.idc.2025.07.005\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disease clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.idc.2025.07.005","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

艰难梭菌的医疗管理在过去十年中发生了重大变化，重点是预防复发性感染。本综述比较了目前关于初始、复发、暴发性和儿童艰难梭菌感染（CDI）治疗的指南，并评估了CDI的机制和现有抗生素的临床使用。艰难梭菌对万古霉素、非达霉素和甲硝唑具有复杂的耐药机制，这可能在治疗结果中起作用。替加环素和利福昔明等抗生素以及抗毒素B的单克隆抗体可在辅助治疗中发挥作用。正在开发的其他疗法包括新的窄效治疗抗生素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Advances in the Medical Treatment of Clostridioides difficile Infection.

Clostridioides difficile medical management has changed significantly over the past decade with emphasis on preventing recurrent infection. This review compares current guidelines on the treatment of initial, recurrent, fulminant, and pediatric C difficile infection (CDI) and evaluates the mechanisms and clinical use of available antibiotics for CDI. C difficile has complex resistance mechanisms to vancomycin, fidaxomicin, and metronidazole which may play a role in treatment outcomes. Antibiotics such as tigecycline and rifaximin as well as monoclonal antibodies against toxin B may play a role in adjunctive therapy. Additional therapies under development include new narrow therapeutic antibiotics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Infectious disease clinics of North America 医学-传染病学

CiteScore

8.30

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Infectious Disease Clinics of North America updates you on the latest trends in the clinical diagnosis and management of patients with infectious diseases, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in infectious disease, including clinical microbiology, compromised host infections, gastrointestinal infections, global health, hepatitis, HIV/AIDS, hospital-acquired infections, travel medicine, infection control, bacterial infections, sexually transmitted diseases, urinary tract infections, and viral infections.